Haematology News and Research

RSS

Anemia: A global health problem with wide disparities

Anemia affected nearly 2 billion people in 2021, impacting women to a greater degree than men. In a new study covering three decades of global anemia data (1990–2021), a complex picture emerges of how several key factors play into the divergence in success stories among men, women, and children.

31 Jul 2023

Sickle cell disease: A global call to action

Reducing the burden of Sickle Cell Disease (SCD) requires substantial financial and political commitment to improving data-collection, diagnosis, treatment and training - doing so will positively impact the lives of millions of patients and families worldwide - says a new Commission published in The Lancet Haematology journal.

12 Jul 2023

Study offers new insights into why some CAR T-cells persist in children with leukemia

New insights explaining why some children have a longer remission than others after having cutting-edge CAR T-cell therapy for leukemia have been revealed by researchers at UCL, Great Ormond Street Hospital, and the Wellcome Sanger Institute.

6 Jul 2023

Researchers develop a prediction tool for blood cancer therapies

Since its introduction in 2015, a prediction tool developed by the European Society of Medical Oncology has been providing support worldwide in the assessment of the clinical benefits of new cancer therapies.

20 Jun 2023

New base-edited T-cells proven effective to treat lymphoblastic leukemia

Three young patients with relapsed T-cell leukemia have now been treated with base-edited T-cells, as part of a 'bench-to-bedside' collaboration between UCL and Great Ormond Street Hospital for Children (GOSH).

15 Jun 2023

Study provides a more complete picture of sickle cell disease mortality burden

A new study suggests the number of deaths due to sickle cell disease is 11 times higher than what is indicated from mortality data sources alone. Sickle cell disease is not just underdiagnosed, but it also increases risk of infection and of death from conditions like stroke, heart problems, kidney problems, and pregnancy complications.

13 Jun 2023

Researchers report positive results from Phase 2 clinical trial of investigational treatment against long COVID fatigue

Researchers from the University of Oxford have reported findings from a Phase 2 clinical trial investigating the efficacy of an investigational treatment against long COVID fatigue.

3 May 2023

HORIBA introduces simple in-house PCR test for faster strangles diagnosis

NORTHAMPTON, UK (27th April 2023) – HORIBA UK Veterinary is supporting Strangles Awareness Week 2023 to educate and improve biosecurity for this devastating equine specific disease.

From HORIBA Scientific UK 27 Apr 2023

New computational method identifies routes of cellular differentiation in acute myeloid leukemia

Researchers have developed a new method to distinguish between cancerous and healthy stem cells and progenitor cells from samples of patients with acute myeloid leukemia (AML), a disease driven by malignant blood stem cells that have historically been difficult to identify.

24 Apr 2023

Novel immunotherapy-based approach for low-grade lymphomatoid granulomatosis improves patient survival

Results from a clinical trial conducted by researchers at the National Institutes of Health (NIH) show that people with low-grade lymphomatoid granulomatosis who are treated with interferon alfa-2b, a type of immunotherapy, can live for decades after diagnosis.

4 Apr 2023

Study shows how neutrophils play a key role in cancer immunotherapy success

Cancer immunotherapies that recruit a patient's own immune system to destroy tumors have transformed the treatment of many types of cancer. Yet these therapies do not elicit universally good treatment responses.

30 Mar 2023

Monthly prophylactic fitusiran injections effective in reducing bleeds in patients with hemophilia A or B

Monthly prophylactic injections of fitusiran are effective in reducing bleeds in patients with hemophilia A or B, according to randomized controlled trials publishing simultaneously in The Lancet and The Lancet Haematology journals.

30 Mar 2023

Hematology patients generate robust immune responses against SARS-CoV-2 after vaccination

Researchers found that, despite being heavily immunocompromised, hematology patients generate strong cellular immune responses against SARS-CoV-2 after vaccination, on par with that of healthy individuals.

29 Mar 2023

Study identifies a potential new targeted drug for treating acute myeloid leukemia

Targeted drugs have been developed to supplement chemotherapy in the treatment of cancer. These drugs only affect cancer cells, leaving healthy cells alone.

23 Feb 2023

Fetal cell program appears to protect against acute myeloid leukemia

During the fetal stage, a number of so-called cell programs run that are vital to the development of the fetus.

21 Feb 2023

Integrating AI with infrared imaging to improve colon cancer diagnosis

Artificial intelligence and infrared imaging automatically classify tumors and are faster than previous methods.

14 Feb 2023

New milestones for the treatment of hemophilia

Hemophilia A is the most common severe form of hemophilia. It affects almost exclusively the male sex. The disease can usually be treated well, but the medicines known so far do not help all of those affected.

9 Feb 2023

Researchers discover a highly potent biomarker for clinical response to CAR-T cell therapy

A MedUni Vienna research team has discovered a highly potent biomarker for clinical response to CAR-T cell therapy, describing the prerequisites for optimal use of this novel therapy for lymphoma treatment.

9 Jan 2023

GOSH delivers world-first base-edited cell therapy for a patient with relapsed T cell leukemia

A patient with relapsed T cell leukemia has been given base-edited T-cells in a world-first use of a base-edited cell therapy, in a 'bench-to-bedside' collaboration between UCL and Great Ormond Street Hospital for Children (GOSH).

12 Dec 2022

Study shows potential benefits of efgartigimod as a treatment for immune thrombocytopenia

Patients taking efgartigimod, a drug being studied for use to treat chronic primary immune thrombocytopenia (ITP), exhibited a significantly greater improvement in platelet counts which are essential to clotting and stopping bleeding, compared to those taking a placebo, according to results reported from the ADVANCE IV clinical trial, which was conducted globally, including at Georgetown University Medical Center.